Indoleamine 2,3-dioxygenase, an emerging target for anti-cancer therapy.

Area of Science:

• Immunology
• Oncology
• Biochemistry

Background:

• Tumor growth is often facilitated by immune suppression, preventing effective anti-tumor responses.
• Indoleamine 2,3-dioxygenase (IDO), an enzyme degrading tryptophan, is a key mediator of this immune escape.
• IDO activity leads to tryptophan depletion and metabolite accumulation, inhibiting T cell activation and promoting regulatory T cells.

Purpose of the Study:

• To review the role of IDO in peripheral immune tolerance.
• To examine evidence of IDO dysregulation in human cancers.
• To discuss the progress in developing IDO inhibitors for cancer therapy.

Main Methods:

• Literature review focusing on IDO's function, role in cancer, and therapeutic inhibition.
• Analysis of preclinical data from tumor models.
• Examination of clinical data linking IDO expression to patient survival.

Main Results:

• IDO mediates peripheral immune tolerance by suppressing T cell responses.
• Increased IDO expression is linked to poorer survival rates in cancer patients.
• IDO inhibition enhances anti-tumor activity of chemotherapy and immunotherapy in preclinical models.

Conclusions:

• IDO is a significant factor in cancer immune evasion and poor prognosis.
• IDO inhibitors represent a promising novel therapeutic strategy for various malignancies.
• Combination therapies involving IDO inhibitors may improve treatment outcomes.